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Introduction: Cell plasticity is crucial in cloning to allow an efficient nuclear reprogramming 
and healthy offspring. Hence, cells with high plasticity, such as multipotent mesenchymal stem 
cells (MSCs), may be a promising alternative for horse cloning. In this study, we evaluated the 
use of bone marrow-MSCs (BM-MSCs) as nuclear donors in horse cloning, and we compared 
the in vitro and in vivo embryo development with respect to fibroblasts. 
Materials and methods: Zona-free nuclear transfer was performed using BM-MSCs (MSC 
group, n=3432) or adult fibroblasts (AF group, n=4527). Embryos produced by artificial 
insemination (AI) recovered by uterine flushing and transferred to recipient mares were used 
as controls (AI group). 
Results: Blastocyst development was higher in the MSC group than in the AF group (18.1% vs 
10.9%, respectively; p<0.05). However, pregnancy rates and delivery rates were similar in both 
cloning groups, although they were lower than in the AI group (pregnancy rates: 17.7% [41/232] 
for MSC, 12.5% [37/297] for AF and 80.7% [71/88] for AI; delivery rates: 56.8% [21/37], 41.5% 
[17/41] and 90.1% [64/71], respectively). Remarkably, the gestation length of the AF group was 
significantly longer than the control (361.7±10.9 vs 333.9±8.7 days), in contrast to the MSC 
group (340.6±8.89 days). Of the total deliveries, 95.2% (20/21) of the MSC-foals were viable, 
compared to 52.9% (9/17) of the AF-foals (p<0.05). In addition, the AF-foals had more physiologi-
cal abnormalities at birth than the MSC-foals; 90.5% (19/21) of the MSC-delivered foals were 
completely normal and healthy, compared to 35.3% (6/17) in the AF group. The abnormalities 
included flexural or angular limb deformities, umbilical cord enlargement, placental alterations 
and signs of syndrome of neonatal maladjustment, which were treated in most cases. 
Conclusion: In summary, we obtained 29 viable cloned foals and found that MSCs are suitable 
donor cells in horse cloning. Even more, these cells could be more efficiently reprogrammed 
compared to fibroblasts.
Keywords: equine, cloning, MSC, SCNT
Introduction
Nuclear transfer (NT) efficiency is based on the donor cell reprogramming capability 
to a totipotent state, commanded by the recipient oocyte.1 Consequently, cell plasticity 
is crucial to guarantee the progression of embryo development and to have healthy 
offspring after cloning.
Notable differences in cloning efficiencies are regularly observed in different mam-
malian species when cells obtained from different tissues are used. Skin fibroblasts 
are the most common cells used, but cells derived from liver,2 kidney,3 granulosa,4,5 
and mesenchymal stem cells (MSCs) have also been tested. In the last years, cloning 
with MSCs has been evaluated in different farm animal species, such as porcine,6–11 
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bovine,12,13 caprine,14 ovine,15 and equine.16 Although higher 
blastocyst rates were observed by using MSCs instead of 
fibroblasts in most reports, only porcine and bovine offspring 
has been obtained from MSC cloning procedures.6,7,11,13 The 
developmental ability of embryos reconstructed using MSCs 
has been associated with their epigenetic, imprinting and 
pluripotency gene expression profile, which were similar 
to in vitro fertilized embryos.7,12 In the horse, MSC-derived 
embryos also showed higher blastocyst rates than fibroblast-
derived embryos, but no offspring was obtained.16 However, 
this was the only report that evaluated equine MSCs’ potential 
as nuclear donors, and only a single MSC line derived from 
the umbilical cord was used in this case.16
Among many types of stem cells, MSCs are multipotent 
stem cells which are easy to maintain in culture and have the 
capacity to differentiate into several cell types. In the horse, 
MSCs have been isolated from different tissues including 
bone marrow (BM-MSC),17,18 umbilical cord,19–21 adipose 
tissue22 and blood,23 and are mostly used in regenerative 
medicine.24–26 Moreover, mesenchymal-like progenitors were 
also derived from equine-induced pluripotent stem cells 
(iPSCs).27 Equine MSCs have been shown to express some 
pluripotency markers, including OCT4 and NANOG,28 and 
to differentiate in adipocytes, chondrocytes and osteocytes, 
which demonstrated their multipotency in vitro.16
Until now, healthy foals were born only by using fetal and 
adult fibroblasts as nuclear donors,5,16,29–32 with high rates of 
embryonic losses and postnatal mortality as typical outcomes, 
though. The most common defects observed in cloned foals 
included limb deformities, umbilical abnormalities and 
failure of passive transfer,16,31,33–35 probably due to inefficient 
reprogramming of the donor cell.
In this study, we report the birth of foals cloned by MSCs 
for the first time. We evaluated the efficiency of BM-MSCs 
as nuclear donors and compared both in vitro and in vivo 
developmental potential of MSC-derived embryos compared 
to fibroblast-derived embryos. Moreover, we focused on 
evaluating the clinicopathologic status of the foals in order 
to determine the effect of the nuclear donor cell on clones.
Materials and methods
Reagents
All chemicals were obtained from Sigma Chemical Company 
(St Louis, MO, USA), except indicated otherwise.
Animal care and use of research animals
This study was carried out following the Guide for the Care 
and Use of Agricultural Animals in Agricultural Research 
and Teaching. The protocols involving animal manipulations 
were approved by the Institutional Committee for the Care 
and Use of Experimental Animals of the San Martin National 
University, Buenos Aires, Argentina (CICUAE-UNSAM, 
Permit Number: 001/16).
Oocyte collection, in vitro maturation 
and preparation for enucleation
Both cumulus–oocyte complex collection from the ovaries and 
in vitro maturation were performed as previously described 
by Olivera et al.16 Briefly, the cumulus–oocyte complexes 
were matured in vitro in bicarbonate-buffered TCM-199 
(31100-035, Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 1 µL/mL insulin-transferrin-selenium 
(51300-044, Thermo Fisher Scientific), 10% fetal bovine 
serum (FBS; 10499-044, Thermo Fisher Scientific), 100 mM 
cysteamine (M-9768), 1 mM sodium pyruvate (P2256), 2% 
antibiotic–antimycotic (ATB; penicillin, streptomycin and 
amphotericin B; 15240-096, Thermo Fisher Scientific) and 
0.1 mg/mL of follicle-stimulating hormone (NIH-FSH-P1; 
Folltropin®, Bioniche, Belleville, ON, Canada) in 5% CO2 
and humidified air at 39°C for 21–24 h. Mature oocytes were 
denuded of cumulus cells with hyaluronidase solution (H4272, 
1 mg/mL in Tyrode’s albumin lactate pyruvate medium buff-
ered with N-2-hydroxyethylpiperazine-N-2-ethane sulfonic 
acid36). After that, the zona pellucida of the oocytes was 
removed by incubation in 1.5 mg/mL pronase (p-8811) for 
3–8 min at 35°C in order to proceed to zona-free enucleation.
Nuclear donor cell culture
NT was performed with two different nuclear donor cells: 
fibroblasts and BM-MSCs. In both cases, they were obtained 
with the owner’s consent and by minimizing animal sufferings 
or stress. For fibroblast culture, skin biopsies were obtained 
from four different female horses of Polo Argentino breed as 
previously reported.16 BM-MSCs were isolated from the bone 
marrow aspirates of the sternum of four different horses of 
Polo Argentino breed (three female and one male). To achieve 
this, horses were kept under sedation with 3 mL Xilacina 100 
(Richmont Vet Pharma, Buenos Aires, Argentina) and 0.5 mL 
Turbogesic (Ekinos, Buenos Aires, Argentina), and local anes-
thesia was provided with 2% lidocaine (20 mL). Bone marrow 
aspirates were collected with a Jamshidi needle by giving pres-
sure over the bone (∼300 mL). Bone marrow aspirate was then 
stored in a blood bag treated with sodium citrate and shipped 
to the lab at 8°C within 3 h. Once at the lab, the aspirate was 
passed and filtered, and then washed with 20 mL of DMEM 
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Nuclear transfer of MSCs improve horse cloning
then plated onto 150 mm  adherent dishes. Both fibroblasts and 
BM-MSCs were cultured in DMEM with 10% FBS, 1% ATB 
and 1 µL/mL of ITS in 5% CO2 in humidified air at 39°C. After 
4–7 days, they were subcultured and expanded until freezing. 
Cycle arrest of donor cells was induced by growth to conflu-
ence in 0.5% FBS for 2–3 days before NT.
Characterization of isolated MSCs
In order to confirm that MSC cells were obtained after bone 
marrow processing, we evaluated the expression of typical 
horse mesenchymal markers by flow cytometry and their 
chondrogenic, adipogenic and osteogenic differentiation 
capabilities. First, the MSCs were trypsinized and resus-
pended in blocking buffer (Dulbecco’s PBS/bovine serum 
albumin 0.1%+10% FBS) with specific antibodies diluted 
1/100 for 30 min at room temperature. The mesenchymal 
markers used were CD29 (561795, BD Pharmingen, Franklin 
Lakes, NJ, USA), CD44 (A14749, Thermo Fisher Scientific), 
CD90 (555595, BD) and CD105 (560819, BD), and we 
included CD34 (555821, BD) as a negative control of the 
hematopoietic linage to ensure the quality of our samples. 
Following washing with Dulbecco’s PBS, cell analysis was 
performed with a BD Accuri cytometer. These analyses were 
done in two different BM-MSC lines randomly selected for 
this purpose. Multilineage differentiation of the MSC cells 
was performed as previously described.16
Oocyte enucleation, NT and embryo 
reconstruction
Oocyte enucleation and NT were performed as previously 
described.16 Briefly, each zona-free ooplast was individually 
attached to a single donor cell (fibroblast or BM-MSC) by using 
1 mg/mL phytohemagglutinin (L8754) dissolved in TCM-199. 
A double direct current pulse of 1.2 kV/cm (30 µs, separated by 
0.1 s) was given to allow membrane fusion. The fusion medium 
used was 1 mg/mL polyvinyl alcohol, 0.3 M mannitol, 0.05 
mM CaCl2 and 0.1 mM MgSO4. After fusion, the reconstructed 
embryos were individually placed in 5 µL droplets of DMEM/
F12 for 2.5 h to allow nuclear reprogramming. Chemical activa-
tion was performed with 8.7 µM ionomycin (I24222, Thermo 
Fisher Scientific) in Tyrode’s albumin lactate pyruvate medium 
buffered with HEPES for 4 min followed by culture in 1 mM 
6-dimethylaminopurine (D2629) and 5 mg/mL cycloheximide 
(C7698) in drops of DMEM/F12 for 4 h.
Embryo culture
Three zona-free reconstructed embryos of each experimental 
group were cultured together in microwells in 100 µL  droplets 
of DMEM/F12 containing 1% ATB and 10% FBS in the pres-
ence of a humidified gas mixture (5% CO2, 5% O2, 90% N2) 
at 39°C. Cleavage was evaluated 72 h after activation when 
half of the medium was renewed. After 7 and 8 days of cul-
ture, blastocyst formation was assessed. The blastocysts were 
transferred to synchronized mares either on day 7 or on day 8.
$UWLÀFLDOLQVHPLQDWLRQ
The in vivo embryos used as controls were produced by 
artificial insemination (AI) during the two breeding seasons 
(2014–2015 and 2015–2016, Southern Hemisphere). The 
donor mares’ cycles were followed by transrectal touch and 
echography until a follicle larger than 35 mm was observed. 
At that time, ovulation was induced with 1 mg/mL deslorelin 
(Deslogest; Over, Santa Fe, Argentina) and the insemination 
was performed with 500×106/mL spermatozoa. At day 8 post-
insemination, blastocysts were recovered by uterus flushing. 
The flushing solution was passed through a filter that did not 
allow blastocysts to pass through. These embryos were then 
washed with holding medium and transferred to recipient 
mares as described in the following section.
Embryo transfer to recipient mares and 
clone birth
Non-surgical embryo transfers to recipients were performed 
in 2014–2015 and 2015–2016 in Buenos Aires, Argentina, 
during spring season. For NT embryos, one, two or three 
blastocysts were transferred per recipient mare, whereas for 
in vivo generated embryos, one blastocyst was transferred 
per recipient mare. Mare examination, estrus synchronization 
and embryo transfer were performed as previously described 
by our group.16 Pregnancies were diagnosed by transrectal 
ultrasonography 7–15 days after embryo transfer. During 
pregnancy, fetal movements, placental quality, umbilical 
abnormalities and heart rate were monitored. In addition, the 
quality of amniotic fluid was analyzed in order to detect fetal 
suffering as soon as possible. Between 20 and 30 days before 
expected parturition, the pregnant mares were transported to 
an equine hospital (KAWELL, Equine Rehabilitation Center, 
Solís, Argentina) to give birth.
Evaluation of clinical status and scoring of 
abnormalities
Foals were analyzed for different pathologies after birth. In 
order to standardize grading of severity of the abnormalities, 
a different score was used for each abnormaility.33 One of the 
pathologies was a congenital articular contracture of the carpus 
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marked flexion. To classify this pathology, limbs were scored 
as follows: 0=straight limbs; 1=slight joint retraction corrected 
without treatment within days after birth; 2=moderate changes 
(valgus or tendon contracture) treated by application of ban-
dages, splints and antibiotic oxytetracycline, corrected in less 
than a month; 3=moderate changes requiring long treatment or 
surgery; 4=severe contraction not correctable but compatible 
with life; and 5=severe contraction not correctable and incom-
patible with life. Another pathology was the syndrome of neo-
natal maladjustment (SNM). After 48 h of birth, the presence 
of signs of hypoxic ischemic encephalopathy was evaluated 
and the following scores were assigned: 0=clinically normal 
foals; 1=slightly weak foals with prolonged time to stand and 
suckle, but these signs were overcome without treatment; 
2=weak foals without the ability to stand and suckle, but these 
signs were resolved within 24–72 h with palliative treatment; 
3=markedly maladjusted foals with hypoxic signs that were 
recovered with intensive care; 4=markedly maladjusted foals 
with hypoxic signs that were recovered with intensive care; 
however, slight alterations persisted compatible with life but 
not with the sporty performance; and 5=severely maladjusted 
and the foal died. At birth, the umbilical cord associated with 
the placenta, the external umbilical opening and the internal 
remnants were also evaluated by transabdominal ultraso-
nography. The umbilicus was scored as follows: 0=normal 
and broke without assistance; 1=slightly enlarged (2–3 cm); 
2=moderately enlarged (>3 cm) and ligatures at parturition 
were required; 3=markedly enlarged (>3 cm) and surgical 
removal required; and 4=omphalocele. In addition, anatomic 
characteristics of the placenta were evaluated at foals’ birth and 
the pathologies related to this organ were scored as follows: 
0=normal placenta; 1=placenta >12% of the foal weight or 
<8% and/or with slight changes in its structure; 2=placenta 
>12% of the foal weight or <8% and/or with moderate changes 
in its structure (edema, villi, abnormal color, secretions, tissue 
folds); 3=placenta >12% of the foal weight or <8% and/or 
with big changes in its structure (edema, villi, abnormal color, 
secretions, tissue folds); and 4=placental retention.
Neonatal hospitalization
All the cloned foals were hospitalized in a preventive manner. 
After birth, oxygen therapy was given and the colostrum of the 
mother was measured. In those cases where the colostrum was 
<15° Brix, 1 L of colostrum from the hospital stock was given 
to the neonates. Moreover, a preventive glycerin enema was 
also supplied and the neonates were under control until they 
eliminated meconium. Three hours after birth, laboratory stud-
ies were performed, including blood count, creatinine,  lactate, 
blood gases and electrolytes. Twelve hours after birth, the glu-
taraldehyde test was performed to evaluate passive transfer, and 
a clot formation in <5 min was taken as a reference value. In 
case it coagulated in >5 min, parenteral plasma was transferred 
to the foal in a preventive manner until correct immunization 
was achieved. Depending on the status of the foal, veterinary 
treatment was established and the discharge was assigned when 
the foal’s conditions were suitable for field management.
&RQÀUPDWLRQRIFORQHV
Once the foals were born, the genome of each foal was ana-
lyzed in order to confirm that they were clones. To achieve this, 
15 loci of the foal and the respective donor animal were com-
pared in the Laboratorio de Genética Aplicada Sociedad Rural 
Argentina, Buenos Aires, Argentina. The evaluated loci were 
AHT4, AME, ASB2, HMS3, HMS7, HTG4, LEX33, HMS2, 
AHT5, ASB17, ASB23, HMS6, HTG10, LEX3 and VHL20.
Statistical analysis
Statistical analysis for the results of in vitro and in vivo 
embryo development was performed using chi-square test or 
nonparametric Fisher’s exact test. Gestational periods, weight 
at birth and days of hospitalization were compared by one-
way analysis of vairance test. In all cases, the software used 




of the bone marrow–derived cells
After immunofluorescence cell staining and flow cytometry, 
we observed that the isolated cells were positive for the 
four MSC surface markers, including CD29, CD44, CD90 
and CD105, and negative for the hematopoietic cell marker 
CD34 (Figure 1A). Moreover, we assessed the differen-
tiation capability of these cells into osteocytes, adipocytes 
and chondrocytes, confirming their multipotent capability 
(Figure 1B). Both these experiments and the adherence of 
the cells to plastic suggested that the isolated cells were of 
mesenchymal origin instead of hematopoietic origin.
In vitro development of zona-free 
aggregated horse embryos reconstructed 
ZLWK%006&RUÀEUREODVWVDVQXFOHDU
donors
In vitro development of horse cloned embryos reconstructed 
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Nuclear transfer of MSCs improve horse cloning
in Table 1. A total of 7959 zona-free reconstructed embryos 
were generated for this experiment, obtaining 1114 blas-
tocysts in total. Both cleavage and blastocyst production 
were higher when BM-MSCs were used as nuclear donors 
(p<0.05). Cleavage rates were 85.6% (3875/4527) vs 90.2% 
(3095/3432), and blastocyst rates were 32.6% (492/1509) 
and 54.4% (622/1144) for adult fibroblast (AF) and MSC 
groups, respectively.
In vivo development of zona-free 
aggregated horse embryos reconstructed 
ZLWK%006&RUÀEUREODVWVDVQXFOHDU
donors
After embryo transfer, we examined the pregnancy rates, 
loss of early and late pregnancies and the number of viable 
offspring for each group (Table 2). Both AF and MSC clon-
ing groups were compared with the AI group as an in vivo 
control. As expected, pregnancy rates were significantly lower 
in AF and MSC groups compared to the AI group: 41/476 
(17.7%) and 37/594 (12.5%) vs 71/88 (80.7%) (p<0.05). 
Moreover, higher embryo loss rates were observed for these 
groups, especially during the first trimester of gestation: 46% 
(19/41) of pregnancies were lost in the AF group between 0 
and 3 months of gestation and 32.4% pregnancies (12/37) 
were lost in the MSC group (p=NS). No fetal losses were 
observed in the in vivo group after 90 days of gestation, 
although 12.2% (5/41) and 10.8% (4/37) of fetal losses were 
recorded for the AF and the MSC groups, respectively. A total 
of 29 foals were born alive between both cloning groups and 
63 in the AI control group, giving a cloning efficiency per 
recipient mare of 3.9% in the AF group, 6.7% in the MSC 
group and 71.6% in the AI group. Although foal delivery rates 
were similar between both cloning groups, healthy offspring 
rates were significantly higher in the MSC group compared 
to the AF group, with 95.2% (20/21) of the delivered foals 
being viable in the MSC group vs 52.9% (9/17) in the AF 
group (p<0.05; Figure 2).
Clinical status of delivered foals
In order to determine the capacity of the fibroblasts or BM-
MSCs to generate healthy foals after cloning, we compared 
Figure 1 Evaluation of the mesenchymal status of the bone marrow–derived cells.
Notes: (A&KDUDFWHUL]DWLRQRIFHOOVXUIDFHPDUNHUV&'&'&'DQG&'RIPHVHQFK\PDORULJLQDQG&'RIKHPDWRSRLHWLFRULJLQE\ÁRZF\WRPHWU\LQWZR
GLIIHUHQW06&OLQHV7KHKLVWRJUDPVVKRZFHOOÁXRUHVFHQFHLQWHQVLW\RQWKH;D[LVDQGFHOOIUHTXHQF\GLVWULEXWLRQRQWKH<D[LV7KHERQHPDUURZLVRODWHGFHOOVZHUHSRVLWLYH
for the four mesenchymal markers and negative for the hematopoietic marker. (B) Evaluation of multipotent capability of bone marrow–derived cells into (a) chondrogenic, 
(b) adipogenic and (c) osteogenic lineages. The isolated cells were able to differentiate into these three lineages.
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the weight at birth, the days of gestation and the clinical 
status of the delivered clones with those of in vivo foals. 
These results are summarized in Figure 3 and Table 3. The 
average weight at birth of the AF foals was statistically higher 
than the average weight at birth of the MSC foals: 49.6±8.5 
kg (n=17) vs 45±5.3 kg (n=21), respectively (p<0.05). Con-
sidering that AI Polo Argentino horses are born with 45–55 
kg on an average (according to the information obtained 
from the  Argentinian equine hospital Kawell), both clon-
ing groups were in the range of normality (Figure 3). The 
gestation period in this breed may range between 310 and 
365 days. In this study, MSC foals’ pregnancy lasted on an 
average 340.6±8.9 days (n=21), which correlates with the 
gestation of the in vivo foals, 333.9±8.7 days on an average 
(n=64; p=nonsignificant). However, gestation length of the 
AF foals (n=17) was significantly higher than those of the 
Table 1 ,QYLWURGHYHORSPHQWRI=)5(VUHFRQVWUXFWHGZLWK%006&RUÀEUREODVWVDVQXFOHDUGRQRUV
Groups ZFREs No. of embryos (wells)* No. of cleaved 
embryos (%)
Blastocyst production
No. % per embryo % per ZFRE
AF 4527 1509 3875 (85.6)a 492 32.6a 10.9a
MSC 3432 1144 3095 (90.2)b 622 54.4b 18.1b
Notes: a,b9DOXHVZLWKGLIIHUHQWVXSHUVFULSWVLQDFROXPQDUHVLJQLÀFDQWO\GLIIHUHQW)LVKHU·VH[DFWWHVWp<0.05). *Embryo aggregation was performed and each well contained 
three ZFREs.
Abbreviations:=)5(V]RQDIUHHUHFRQVWUXFWHGHPEU\RV%006&VERQHPDUURZ²GHULYHGPHVHQFK\PDOVWHPFHOOV$)DGXOWÀEUREODVWV06&PHVHQFK\PDOVWHPFHOO








at 0–3 months  
(%)
Fetal losses  
at 4–11 months  
(%)
Deliveries (%) Viable foals
No. % per  
pregnancy
% per  
delivery
AF 476 232 41 (17.7)a 19 (46)a 5 (12.2)a 17/41 (41.5)a 9 22.0a 52.9a
MSC 594 297 37 (12.5)a 12 (32.4)a 4 (10.8)a 21/37 (56.8)a 20 54.1b 95.2b
AI 88 88 71 (80.7)b 7 (9.9)b 0 (0)b 64/71 (90.1)b 63 88.7c 98.4b
Notes: a,b,c9DOXHVZLWKGLIIHUHQWVXSHUVFULSWVLQDFROXPQDUHVLJQLÀFDQWO\GLIIHUHQW)LVKHU·VH[DFWWHVWp<0.05).
Abbreviations:$)DGXOWÀEUREODVWV06&PHVHQFK\PDOVWHPFHOO$,DUWLÀFLDOLQVHPLQDWLRQHPEU\RVDVFRQWUROV
Figure 2 Eight cloned polo horses derived from the same MSC line, born in August, September and October 2016.
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Nuclear transfer of MSCs improve horse cloning
other two groups, 361.7±10.9 days on an average (p<0.05). 
In addition, AF clones had more clinical complications and 
anatomic defects at birth than MSC clones. In the AF group, 
three of the live-born foals had some degree of flexural or 
angular limb deformity with score ≥2, whereas none of the 
live-born foals from the MSC group had this type of defects. 
The only foal with limb retractions in this group (score=3) 
also presented serious clinical abnormalities including umbi-
licus enlargement (score=3), SNM (score=3) and placental 
disorders (score=3) and died after birth as a consequence 
of colon hypoplasia. In the AF group, six of the not viable 
foals also exhibited limb contractions with score ≥2. Marked 
umbilicus cord enlargements (score ≥3) were also observed 
in 6 of the 17 fibroblast born foals (35.3%); two of them were 
viable and required surgery for treatment. The other four foals 
with this pathology that were not viable also exhibited SNM 
(scores=5, 5, 3 and 1) and limb retractions (scores=4, 4, 3 and 
4) and died after birth. Among the AI foals, one also exhibited 
SNM with score ≥3 and died after birth (1/64, 1.6%), similar 
to the MSC group (1/21, 4.7%). Placental abnormalities 
with score ≥3 were also observed in not viable foals of both 
cloning groups, with no statistical differences between them.
The hospitalization time was also recorded in order 
to determine the care required by the neonates of clon-
ing groups. In all cases, mares pregnant with clones were 
transported to an equine hospital to give birth. Comparing 
the hospitalized days between both cloning groups, we 
observed that AF foals needed much more veterinary care 
than MSC foals (14.3±10.6 vs 6.05±4.1 days, respectively; 
p<0.05), especially the viable foals (21.2±5.4 vs 6.3±4.0 
days, respectively). In contrast, mares pregnant with in vivo 
derived embryos were not hospitalized and gave birth without 
special assistance.
Discussion
We demonstrated for the first time the capability of BM-
MSCs to generate viable healthy offspring after NT in the 
horse. In addition to the scientific relevance of studying 
nuclear reprogramming and horse embryo development 
by this technique, the interest on cloning has increased to 
maintain and reproduce high-quality genetic composition of 
sports animals. For this reason, since the first cloned horse 
was born,37 researchers have focused on improving this tech-
nique in order to increase healthy offspring rates. By using 
BM-MSCs as nuclear donors, we could reach this goal. We 
achieved 95% (20/21) of foals born without any cloning 
defects commonly observed, thus improving the viability 
rates and their general clinical status.
To the best of our knowledge, this study is the first 
report on the use of MSCs in equine NT, but their potential 
Figure 3 Weight at birth and gestational length of the AF and MSC cloned groups.
Notes: The green dashed lines are delimiting the range of normality according 
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Table 3 Clinical status and scoring of abnormalities of delivered cloned foals and in vivo foals
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as nuclear donors has been demonstrated before in other 
mammalian species. As previously reported, higher in vitro 
preimplantation development was observed in bovine,12 
porcine38 and goat14 with MSCs as nuclear donors compared 
to fibroblasts. In the porcine, embryos reconstructed with 
adipose tissue MSCs (aMSCs) resulted in higher blastocyst 
rates compared to peripheral blood MSCs or fibroblast-
reconstructed embryos,11 which reflects the variability among 
different MSC sources. On the other hand, another report in 
the same species showed no differences in in vitro embryo 
development, but higher quality blastocysts were obtained 
when MSCs were used instead of fibroblasts.7 This might 
be related to the gene expression profile of MSC-derived 
embryos which resulted in being similar to in vivo embryos 
unlike fibroblast-derived embryos.38 We obtained higher 
cleavage and blastocyst rates in the MSC group than in the AF 
group, both by using BM-MSCs in this study and umbilical 
cord MSCs in a previous report of our group.16 For in vivo 
embryo development assessment, 617 embryo transfers were 
achieved among the MSC group, the AF group and the AI 
control group. As expected, the AI group showed the highest 
pregnancy rates, and similar pregnancy rates were observed 
between both cloning groups. Regardless of the cell source we 
used for cloning, pregnancy loss of the NT-derived embryos 
was substantial, especially during the first trimester of ges-
tation, which is a common concern when working on this 
technique. Most studies have also reported high pregnancy 
loss after cloning, with usually ≤5% of transferred embryos 
resulting in viable foals.5,16,30,31,37,39–41 However, seven pregnan-
cies from the control group were also lost in the first trimester, 
which suggests that the greatest vulnerability of pregnancy 
occurs during this period.
We observed that the delivery rates between the AF 
group and the MSC group were not significantly different, 
as 41.5% (17/41) of the pregnancies reached their term in 
the AF group and 56.8% (21/37) in the MSC group (p=NS). 
However, significant differences were obtained in the viability 
of the delivered foals. Almost all of the MSC-delivered foals 
were viable and healthy, whereas half of the AF-delivered 
foals were alive after birth. Differences were also obtained 
in the weight at birth and in the gestation length (Figure 3). 
Higher weight at birth in the AF group may be related to 
longer gestational periods in this group. MSC pregnancies 
lasted similar to AI embryos, in contrast to AF pregnancies 
that lasted longer. The normal gestation length is considered 
to be between 310 and 365 days in Polo Argentino breed. 
Despite 361 days of gestation on an average in the fibroblast 
group which is within the range of normality, there were seven 
foals that were born after longer pregnancy periods (367–382 
days); five of them were born alive and two died after birth. 
These variations in the gestation lengths were not observed in 
the MSC group since all the pregnancies were in the normal 
range. We believe that abnormally longer gestational periods 
are related to placental insufficiency, which could result in 
a reduction of the nutrient supply to the developing fetus. 
Moreover, high creatinine levels were observed in these 
neonatal foals, which revealed the dysfunctional capacity 
of the placenta as the excretory organ of the fetal foals.42
In addition to higher viability rates, almost all the MSC-
derived foals were healthy and did not exhibit any clinico-
pathologic defect after birth. In the AF group, in addition to 
eight neonatal losses, three viable foals presented with limb 
contraction (scores 2 and 3) and umbilicus enlargement (score 
3), which were treated and resolved with specialized care, 
though. Some of these pathologic disorders were also reported 
previously in cloned foals,16,31,33–35 and they were directly related 
to the NT technique. In concordance with our results, cloned 
piglets derived from MSCs did not exhibit any visible defect,7 
which usually could be seen in piglets cloned from fibroblasts.7,43 
Moreover, higher live birth rates were obtained from peripheral 
blood–derived MSCs as nuclear donors than fibroblasts in the 
same species.11 Similar observations were made in the bovine, as 
higher offspring rates were obtained when amniotic fluid MSCs 
(25%) and aMSCs (12.5%) were used as nuclear donors with 
respect to the overall efficiency in this species.13,44
Another finding that revealed differences in the clinical 
status between the foals of both cloning groups was the time 
the neonates spent in hospital with veterinary care after birth. 
Despite the fact that all pregnant mares gave birth in an equine 
hospital as a precaution, MSC foals left medical cares within 
1 week on an average, whereas viable AF foals required 
hospitalization for 3 weeks. This information highlights the 
intensive care assistance the fibroblast-derived foals required 
after birth in comparison to the MSC-derived foals.
We consider that the differences between the MSC-
embryos and the AF-embryos were due to the initial dif-
ferentiation status of each cell type. We propose that nuclear 
reprogramming was improved when BM-MSCs were used 
because of their multipotent capacity. While some articles 
defend the idea that there is no correlation between the stem-
ness of the cell and the cloning efficiency,45–47 others have 
demonstrated that the differentiation status influences the 
developmental potential of the reconstructed embryos. There 
are many studies that observed higher  developmental rates of 
the embryos when less-differentiated cells were used com-
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Nuclear transfer of MSCs improve horse cloning
Moreover, it has been shown that cells showing high expres-
sion of Oct4 are more efficient as NT donor cells,8 which 
reinforces this statement. On the other hand, cloning with 
iPSCs as nuclear donors in domestic animals has not been 
promising, in spite of their pluripotent capacity.16,47,49,50 These 
differences between the efficiencies of MSCs and iPSCs may 
be related to the resident expression of the exogenous plu-
ripotent genes oct4, cmyc, klf4 and sox2 in integrative iPSC 
lines,16,51 the suboptimal culture conditions52 or the difficulties 
regarding cell cycle synchronization of the iPSCs which could 
compromise the success of cloning.53 In contrast, MSCs are 
multipotent stem cells that are easy to maintain in culture 
and behave similar to fibroblasts in vitro, which facilitates 
their manipulation and cell cycle synchronization. Not only 
the multipotent capacity of the MSCs, but also their easy 
manipulation makes these cells advantageous for cloning. 
In summary, our study strongly suggests that BM-MSCs are 
suitable nuclear donor cells and that they can produce healthier 
cloned horses through NT, as compared with fibroblasts. In 
addition, further experiments are required to compare other 
MSC sources for NT, such as aMSCs or peripheral blood 
MSCs, to strengthen our work. Until now, equine MSCs have 
been used in regenerative medicine for therapeutic applica-
tions,54–56 but our report is the first one that has used these cells 
as nuclear donors with proper evidence that healthy offspring 
can be generated. The birth of 29 viable foals in both cloning 
groups supports our conclusions.
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